Blog Entry: Usage Of Stating On Patients With Chronic Heart Failure As Of The Results Essay Samples

Statins are commonly known to be used for both primary and secondary prevention of atherosclerotic cardiovascular disease, since they lower the level of cholesterol in blood. In addition, statins have anti-inflammatory and antithrombotic effects as well as provide vasodilatation by stimulating nitric oxide synthesis. Consequently, people with chronic heart failure(CHF) benefit from statins, especially because CHF often leads to inflammation in myocardial tissue.
The purpose of the study is to evaluate the relation between statins used for CHF and outcomes of survival for CHF. The information for the study is taken from two observational studies which involved 5200 patients. Firstly, researchers collected information Elite 2 study which included 3132 people. Secondly, they came up with a particular method by dividing all the patients into five different groups: patients diagnosed with CHF, patients with no-ischemic history who were treated with statins, patients who were treated with higher statins, patients who suffered from severe of cardiac failure, and long period follow-up patients. All data were collected from five different European research centers. Main data includes: age, sex, left ventricular ejection fraction (LFEF), NYHA class, body mass index, medications and survival status. What is also important, the causes of HF, and whether patients have ischemic etiology (IE), or NEI, were considered. Moreover, throughout the research, the hazard ratio (HR), 95% confidence intervals (CI,) and P values were obtained. After all data were collected, corresponding graphs on it were made by researchers.
Results displayed that Patients in ELITE 2 were mostly young and suffering from IE, many of them administering beta blockers at baseline; there also was no significant improvement in rate of survival after using statins compared to patients with NIE. Nevertheless, it might have been due to the fact only 46 patients participated in the research. Concurrently, European centers achieved better results in a reduction of mortality for patients with IE or NIE when taking statins through their researches. The results were the same after adjustment of age, sex and LVEF. What is more, a substantial reduction in deaths for patients with IE in NYHA class I/II was indicated by the researches. On the contrary, there was reduction in deadly outcomes for patients with NIE. However, fewer deaths occurred for those with NYHA class III/IV.
Lowering cholesterol level is crucial for patients with coronary artery disease, a common cause of HF. As a result, using statins is beneficial for people suffering from it. The results of study also suggested patients with EI may use statins, because it provides anti-inflammatory action even in low dosage. It was shown that the quantity of deadly outcomes for patients with NIE and NYHA class I/II did not change due to absence of inflammation. However, this might have happened because these patients were taking statins before the study, which may affect the results of such studies. In addition, only total cholesterol level was measured while ignoring the index of body mass, kidney and overall heart functioning; these stand as drawbacks of the study. All in all the analysis concludes patients with CHF should undergo stains therapy according to their NYHA and IE.